Recent insights into platinum drug resistance in cancer
- PMID: 16904407
- DOI: 10.1016/s1368-7646(98)80005-8
Recent insights into platinum drug resistance in cancer
Abstract
Cisplatin and its analogs have become important components of chemotherapeutic regimens for the treatment of solid tumors, however, their overall effectiveness is limited by the emergence of drug-resistant tumor cells. Resistance to the platinum drugs is multifactorial consisting of mechanisms that prevent the formation of lethal platinum-DNA adducts and mechanisms that operate downstream of the drug/target interaction to promote cell survival. Continued progress in the study of the drug resistance phenotype as well as the development of new platinum analogs may eventually lead to improved therapies and increased survival rates.
Similar articles
-
Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin.J Invest Dermatol. 2003 Jul;121(1):172-6. doi: 10.1046/j.1523-1747.2003.12313.x. J Invest Dermatol. 2003. PMID: 12839578
-
Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.Lung Cancer. 2017 Jan;103:58-65. doi: 10.1016/j.lungcan.2016.11.019. Epub 2016 Nov 28. Lung Cancer. 2017. PMID: 28024697
-
Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs.Drug Resist Updat. 2005 Jun;8(3):131-46. doi: 10.1016/j.drup.2005.04.006. Drug Resist Updat. 2005. PMID: 15894512 Review.
-
Nonclassical platinum antitumor agents: perspectives for design and development of new drugs complementary to cisplatin.Cancer Invest. 1993;11(5):578-89. doi: 10.3109/07357909309011676. Cancer Invest. 1993. PMID: 8402226 Review.
-
Platinum resistance: laboratory findings and clinical implications.Stem Cells. 1993 May;11(3):182-93. doi: 10.1002/stem.5530110304. Stem Cells. 1993. PMID: 8318904 Review.
Cited by
-
Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells.Br J Cancer. 2005 Mar 28;92(6):1149-58. doi: 10.1038/sj.bjc.6602447. Br J Cancer. 2005. PMID: 15726096 Free PMC article.
-
DNA and glutathione interactions in cell-free media of asymmetric platinum(II) complexes cis- and trans-[PtCl2(isopropylamine)(1-methylimidazole)]: relations to their different antitumor effects.J Biol Inorg Chem. 2009 Jan;14(1):75-87. doi: 10.1007/s00775-008-0425-0. Epub 2008 Sep 6. J Biol Inorg Chem. 2009. PMID: 18777181
-
Preclinical perspectives on platinum resistance.Drugs. 2000;59 Suppl 4:1-8; discussion 37-8. doi: 10.2165/00003495-200059004-00001. Drugs. 2000. PMID: 10864225 Review.
-
Identification of the molecular mechanisms underlying the cytotoxic action of a potent platinum metallointercalator.J Chem Biol. 2012 Apr;5(2):51-61. doi: 10.1007/s12154-011-0070-x. Epub 2011 Dec 6. J Chem Biol. 2012. PMID: 23226166 Free PMC article.
-
In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.Br J Cancer. 2002 May 20;86(10):1652-7. doi: 10.1038/sj.bjc.6600290. Br J Cancer. 2002. PMID: 12085218 Free PMC article.
LinkOut - more resources
Full Text Sources